MA(Medical Affairs) 재정의 : 팬데믹 후의 전략 전환과 새로운 우선 과제
Redefining Medical Affairs: Strategic Shifts and Emerging Priorities Post-Pandemic
상품코드 : 1699594
리서치사 : FirstWord Group
발행일 : 2025년 04월
페이지 정보 : 영문
 라이선스 & 가격 (부가세 별도)
US $ 8,000 ₩ 11,611,000
Multi User License (PDF) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. PDF 텍스트 등의 복사 및 붙여넣기 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

COVID-19 팬데믹이 MA(Medical Affairs)에 미친 변혁적 영향을 조사하고, MA(Medical Affairs)가 팬데믹에서 얻은 교훈을 바탕으로 하이브리드 비즈니스 모델을 최적화하고, 의료진(HCP)과의 소통을 강화하는 방법을 자세히 분석합니다. 분석했습니다. 또한 HCP의 진화하는 니즈에 대응하기 위한 디지털 툴과 옴니채널 접근방식의 통합을 검토하고, 이 분야의 미래 전략과 전술에 대한 종합적인 로드맵을 제공합니다.

보고서 내용

주요 기업

  • Bayer
  • BioMarin Pharmaceutical
  • IQVIA
  • McKinsey & Company
KSA
영문 목차

영문목차

This report examines the transformative impact of the COVID-19 pandemic on medical affairs, highlighting its evolution from a supportive function to a strategic partner within pharmaceutical companies. It provides an in-depth analysis of how medical affairs can leverage lessons learned during the pandemic to optimise hybrid working models and enhance engagement with healthcare professionals (HCPs). The report also explores the integration of digital tools and omnichannel approaches to meet the evolving needs of HCPs, offering a comprehensive roadmap for future strategies and tactics in the field. Gain insights into the permanent changes in MSL-HCP interactions, the role of AI in increasing efficiency and the importance of proactive strategies in medical affairs.

Key Questions Answered:

Key Companies:

  • Bayer
  • BioMarin Pharmaceutical
  • IQVIA
  • McKinsey & Company

Partial List of Participating Experts:

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기